SCHEMBL6484254

SCHEMBL6484254

COCCCn1c(-c2ccc(OC)cc2)nc2ccc(OCCCCCC(=O)OC)cc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 7/20 0.50
PDE3A Q14432 7/20 0.50
P2RY12 Q9H244 6/20 0.50
KDM4E B2RXH2 4/20 0.50
ALDH1A1 P00352 3/20 0.50
PDE2A O00408 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
DYRK1A Q13627 3/20 0.48
GAA P10253 2/20 0.46
HSD17B10 Q99714 2/20 0.46
HPGD P15428 1/20 0.46
PIN1 Q13526 3/20 0.45
LMNA P02545 2/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
MC4R P32245 1/20 0.44
TSHR P16473 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MTNR1A P48039 1/20 0.43
MTNR1B P49286 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6485249 0.94 PDE3B (0.50) PDE3BPDE3AP2RY12KDM4EALDH1A1
SCHEMBL6484869 0.94 PDE3B (0.49) PDE3BPDE3AP2RY12KDM4EALDH1A1
SCHEMBL6476172 0.93 PDE3B (0.48) PDE3BPDE3AP2RY12KDM4EALDH1A1
SCHEMBL6483313 0.93 PDE3B (0.50) PDE3BPDE3AP2RY12KDM4EALDH1A1
SCHEMBL6484336 0.93 PDE3B (0.50) PDE3BPDE3AP2RY12KDM4EALDH1A1
SCHEMBL6475050 0.92 PIN1 (0.56) PDE3BPDE3AP2RY12KDM4EALDH1A1
SCHEMBL6481683 0.92 PDE3B (0.49) PDE3BPDE3AP2RY12KDM4EALDH1A1
SCHEMBL6484026 0.91 KDM4E (0.51) PDE3BPDE3AP2RY12KDM4EALDH1A1
SCHEMBL6483132 0.91 PDE3B (0.48) PDE3BPDE3AP2RY12KDM4EALDH1A1
SCHEMBL6486842 0.91 PDE3B (0.47) PDE3BPDE3AP2RY12KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6855714-B2 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives SCHERING AKTIENGESELLSCHAFT (DE) 2005-02-15 US claimed
EP-1404321-A1 1-ALKYL-2-ARYL-BENZIMIDAZOLE DERIVATIVES, THEIR USE FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES Schering Aktiengesellschaft (DE) 2004-04-07 EP claimed
US-20030055057-A1 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutial agents as well as pharmaceutical preparations that contain these derivatives SCHERING AG (DE) 2003-03-20 US claimed
WO-2003004023-A1 1-ALKYL-2-ARYL-BENZIMIDAZOLE DERIVATIVES, THEIR USE FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES SCHERING AKTIENGESELLSCHAFT (DE) 2003-01-16 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055057-A1 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutial agents as well as pharmaceutical preparations that contain these derivatives ARG2, MSR1, ARG1 PDE3B 210/4885PDE3A 226/4885P2RY12 562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.